CymaBay announces presentation on RESPONSE Phase 3 data of seladelpar

CymaBay Therapeutics announced that a late-breaking presentation highlighting results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases, in Boston, MA. Seladelpar is a potent, selective, orally active delpar or PPARdelta agonist, in development for the treatment of adult patients with primary biliary cholangitis. The oral presentation titled “Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis in the RESPONSE Trial: A Phase 3 International, Randomized, Placebo-Controlled Study,” will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease. Charles McWherter, Ph.D., Chief Scientific Officer and President of Research and Development at CymaBay, commented, “We look forward to sharing results from the RESPONSE study, which is the culmination of years of clinical development of seladelpar in patients with PBC examining and confirming it’s treatment effects on cholestatic markers and symptoms. This is an important step forward in the process of obtaining regulatory review and potentially marketing authorization. We are extremely grateful to our team, investigators, and especially patients in the participation and collaboration in this endeavor. It’s a privilege once again to be invited to share these results at The Liver Meeting(R) 2023.”